Zafgen

5 stories
Share surge
After completing its IPO Wednesday with strong demand from investors, Cambridge biotech firm Zafgen saw its shares jump as trading began this morning. The shares in the obesity treatment maker closed up about 22 percent, at $19.56, from the IPO price of $16. The IPO was the 10th by a Massachusetts-based biotech firm so far this year, topping the tally from last year of nine and setting a new record. Discuss
TACKLING SEVERE OBESITY
Zafgen completes $96 million IPO with big demand for shares
zafgen

Zafgen Inc. has completed its initial public offering amid strong demand from investors. The Cambridge biotech firm increased the size of the offering and sold shares at the top of its projected range on Wednesday, raising a total of $96 million. The IPO is the 10th by a Massachusetts-based biotech firm so far this year, topping the tally from last year of nine and setting a new record.

Read More